RHONE-POULENC RORER AND FISONS ANNOUNCE AGREEMENT IN PRINCIPLE TO CO-PROMOTE TILADE(R) AND AZMACORT(R)
COLLEGEVILLE, Pa., and ROCHESTER, N.Y., Jan. 5 /PRNewswire/ -- Rhone Poulenc Rorer Pharmaceuticals Inc. (NYSE: RPR) and Fisons Pharmaceuticals announced today an agreement in principle to co-promote two complementary anti-inflammatory drugs for the treatment of asthma. A combined sales force of 800 representatives will market Rhone- Poulenc Rorer's Azmacort(R) (triamcinolone acetonide), the leading metered dose inhaled steroid in the United States and Fison's Tilade(R) (nedocromil sodium), a new class of anti-inflammatory drug approved for marketing by the Food and Drug Administration on Dec. 31, 1992. "Co-promotion will enable us to focus on the need to treat asthma as an inflammatory disease with virtually every physician in the United States that treats this condition," said Randy Thurman, president of Rhone-Poulenc Rorer Pharmaceuticals Inc. Glenn Mattes, vice president and division manager of the Rorer Division of RPR Pharmaceuticals, Inc., added, "Both the National Heart, Lung and Blood Institute (NHBLI) of the National Institutes of Health and the International Consensus Report on Asthma have recently urged first-line anti-inflammatory treatment of asthma." Asthma is a respiratory condition characterized by symptoms caused by airway obstruction, such as coughing, chest tightness, wheezing and shortness of breath. The condition affects more than 10 million Americans and is one of the leading causes of school and work absences. Although problems are often separated by symptom-free periods, asthma is a chronic disease. "We are looking forward to a very successful co-promotion between Fisons and RPR. Together, we create a formidable force in the asthma market," says Helmo Reulecke, president of Fisons Pharmaceuticals. Tilade is a non-steroid, inhaled, anti-inflammatory agent for asthma. It has been proven safe and effective as a bronchial anti-inflammatory agent in treating mild to moderate asthma in patients, age 12 and older, and contributes significantly to the better management of asthma for this major patient group.
Daily dosing provides patient benefits by reducing both symptoms and bronchial hyperreactivity in asthmatic patients.
Azmacort is indicated for patients who require chronic treatment with corticosteroids for the control of the symptoms of bronchial asthma. Patients administer the metered-dose aerosol via a unique, built-in spacer device. Reulecke concluded, "Tilade and Azmacort each have a unique and important pharmacologic action, and the two drugs play a complementary role in contributing to the successful treatment of asthma." Fisons PLC is a UK-based international company headquartered in Ipswich, Suffolk. Reporting sales of more than $2 billion in 1991, the company employs 14,500 people worldwide and operates in more than 100 countries. Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to the discovery, development, marketing and manufacturing of human pharmaceuticals. The company reported sales of $3.8 billion in 1991 and has invested over $500 million in research and development in 1992. /delval/ -0- 1/5/93 /CONTACT: Ellen Kovak or Eileen Masciale of Fisons Pharmaceuticals, 212-246-0540, or Bob Pearson of Rhone-Poulenc Rorer, 215-454-3872/ (RPR)
CO: Rhone-Poulenc Rorer Pharmaceuticals Inc.; Fisons Pharmaceuticals;
Fisons PLC ST: Pennsylvania, New York IN: MTC SU: JVN
CC -- PH014 -- 1800 01/05/93 14:00 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 5, 1993|
|Previous Article:||TYLER CORPORATION FILES SHELF REGISTRATION|
|Next Article:||HARSCO CORPORATION SEEKS TO ACQUIRE WAYNE BUS COMPANY ASSETS|